Covidien now offers unique solutions for treatment of chronic total occlusions

Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the Viance™ Crossing Catheter and Enteer™ Re-entry System for treating chronic total occlusions (CTOs) endovascularly. The devices are now available in the United States, the European Union (EU) and other select international markets.    

"Management of the lower extremity CTO remains challenging for endovascular physicians," said David B. Jessup, MD of PeaceHealth St. Joseph Medical Center in Bellingham, Washington. "Effective devices for CTO crossing and re-entry can expand the number of patients who have access to endovascular treatment of peripheral arterial disease, which may help patients avoid more invasive treatments and allow physicians to offer amputation-saving procedures."

For effective treatment, physicians must be able to successfully cross lesions. The new tools from Covidien are designed to enable access to the distal end of a lesion, allowing physicians to treat even the most challenging lesions endovascularly. Together, the Viance Crossing Catheter and the Enteer Re-entry System offer a solution that leverages the skill and finesse of the physician rather than brute force or capital equipment.

"Covidien now offers a unique solution for the treatment of CTOs," said Brian Verrier, Vice President and General Manager, Peripheral Vascular, Covidien. "By adding these products to our market-leading peripheral portfolio, we strive to demonstrate our commitment to advancing the treatment of vascular disease worldwide by delivering innovation that achieves both clinical and economic value for our healthcare partners."

Competitive crossing devices rely on more aggressive cutting, grinding or pounding motions and can be more difficult to control. Moreover, the distinctive shape of the re-entry balloon enables it to self-orient within the vessel. No other product on the market utilizes this balloon technology for a re-entry system.    

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Chronic Urticaria: Addressing unmet needs, emerging therapies, and advances in personalized treatment approaches